

Marlyn J Mayo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4729300/publications.pdf>

Version: 2024-02-01

48
papers

4,439
citations

218381

26
h-index

205818

48
g-index

51
all docs

51
docs citations

51
times ranked

3184
citing authors

#	ARTICLE	IF	CITATIONS
1	Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2019, 69, 394-419.	3.6	507
2	Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2020, 72, 671-722.	3.6	473
3	Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid. <i>Gastroenterology</i> , 2015, 148, 751-761.e8.	0.6	470
4	Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study. <i>Gastroenterology</i> , 2014, 147, 1338-1349.e5.	0.6	365
5	Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. <i>Gastroenterology</i> , 2015, 149, 1804-1812.e4.	0.6	330
6	Sertraline as a first-line treatment for cholestatic pruritus. <i>Hepatology</i> , 2007, 45, 666-674.	3.6	274
7	Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. <i>Hepatology</i> , 2008, 48, 1549-1557.	3.6	167
8	Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. <i>Journal of Hepatology</i> , 2019, 71, 357-365.	1.8	148
9	Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. <i>Gut</i> , 2016, 65, 321-329.	6.1	139
10	Extrahepatic Manifestations of Hepatitis C Infection. <i>American Journal of the Medical Sciences</i> , 2003, 325, 135-148.	0.4	133
11	Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial. <i>Journal of Hepatology</i> , 2019, 70, 483-493.	1.8	124
12	Long-Term Efficacy of Sertraline As A Treatment for Cholestatic Pruritus in Patients With Primary Biliary Cirrhosis. <i>American Journal of Gastroenterology</i> , 2003, 98, 2736-2741.	0.2	120
13	Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. <i>Hepatology</i> , 2005, 42, 1184-1193.	3.6	112
14	Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof-of-concept study. <i>Hepatology</i> , 2016, 64, 189-199.	3.6	101
15	NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Hepatology Communications</i> , 2018, 2, 1037-1050.	2.0	96
16	Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. <i>American Journal of Gastroenterology</i> , 2020, 115, 1066-1074.	0.2	74
17	Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1127-1136.	1.9	66
18	Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome. <i>American Journal of Gastroenterology</i> , 2018, 113, 254-264.	0.2	64

#	ARTICLE	IF	CITATIONS
19	A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis. <i>Hepatology Communications</i> , 2019, 3, 365-381.	2.0	58
20	Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history. <i>Hepatology</i> , 2018, 67, 1920-1930.	3.6	55
21	Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2076-2084.e2.	2.4	54
22	Natural History of Primary Biliary Cirrhosis. <i>Clinics in Liver Disease</i> , 2008, 12, 277-288.	1.0	37
23	A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis. <i>Journal of Hepatology</i> , 2022, 77, 353-364.	1.8	36
24	Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2022, 75, 1012-1013.	3.6	34
25	Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis. <i>Liver International</i> , 2022, 42, 112-123.	1.9	31
26	Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1688-1697.e14.	2.4	30
27	Immunosuppressive Treatment Regimens in Autoimmune Hepatitis: Systematic Reviews and Meta-Analyses Supporting American Association for the Study of Liver Diseases Guidelines. <i>Hepatology</i> , 2020, 72, 753-769.	3.6	30
28	Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis. <i>Gut</i> , 2020, 69, 1502-1509.	6.1	28
29	Primary biliary cirrhosis in 2014. <i>Current Opinion in Gastroenterology</i> , 2014, 30, 245-252.	1.0	24
30	Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation. <i>Journal of Hepatology</i> , 2022, 77, 84-97.	1.8	21
31	The Beneficial Effect of Beta-Blockers in Patients With Cirrhosis, Portal Hypertension and Ascites. <i>American Journal of the Medical Sciences</i> , 2016, 351, 169-176.	0.4	20
32	Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 684-692.e6.	2.4	17
33	Mechanisms and molecules: What are the treatment targets for primary biliary cholangitis?. <i>Hepatology</i> , 2022, 76, 518-531.	3.6	17
34	Management of autoimmune hepatitis. <i>Current Opinion in Gastroenterology</i> , 2011, 27, 224-230.	1.0	13
35	Primary Biliary Cholangitis: 2018 Practice Guidance From the American Association for the Study of Liver Diseases. <i>Clinical Liver Disease</i> , 2020, 15, 1-2.	1.0	13
36	The relationship between hepatic immunoglobulin production and CD154 expression in chronic liver diseases. <i>Liver International</i> , 2006, 26, 187-196.	1.9	12

#	ARTICLE	IF	CITATIONS
37	Development of a Successful Scholarly Activity and Research Program for Subspecialty Trainees. American Journal of the Medical Sciences, 2015, 350, 222-227.	0.4	10
38	Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis. JHEP Reports, 2021, 3, 100191.	2.6	10
39	Cholestatic Liver Disease Overlap Syndromes. Clinics in Liver Disease, 2013, 17, 243-253.	1.0	8
40	High Neutrophilâ€“Lymphocyte Ratio and Delta Neutrophilâ€“Lymphocyte Ratio Are Associated with Increased Mortality in Patients with Hepatocellular Cancer. Digestive Diseases and Sciences, 2021, , 1.	1.1	8
41	Similar T-cell oligoclonality in antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Digestive Diseases and Sciences, 2001, 46, 345-351.	1.1	6
42	Patients and patience: the pitfalls of primary biliary cirrhosis trials. Nature Reviews Gastroenterology & Hepatology, 2005, 2, 552-553.	1.7	6
43	Updated Etiology and Significance of Elevated Bilirubin During Pregnancy: Changes Parallel Shift in Demographics and Vaccination Status. Digestive Diseases and Sciences, 2017, 62, 517-525.	1.1	6
44	Managing the Symptoms and Complications of Cholestasis. Clinical Liver Disease, 2020, 15, 120-124.	1.0	6
45	Primary biliary cirrhosis: the future. Clinics in Liver Disease, 2003, 7, 957-969.	1.0	5
46	Simplified care-pathway selection for nonspecialist practice. European Journal of Gastroenterology and Hepatology, 2020, Publish Ahead of Print, .	0.8	2
47	Therapeutics for Pruritus in Cholestatic Liver Disease: Many Treatments but Few Cures. Current Hepatology Reports, 2018, 17, 143-151.	0.4	1
48	Non-PBC, Non-PSC autoimmune cholangiopathy. Current Treatment Options in Gastroenterology, 2000, 3, 121-131.	0.3	0